While toxicity data for these agents are not fully published yet, the known risk of pneumonitis associated with monoclonal antibodies targeting PD-(L)1 foreshadows the possibility of increased toxicity rates for patients treated with dual inhibitors. The gene discussed is CD274; the disease is pneumonitis.